Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Pharmaceutical Research

• Publication date

  1986-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1023/A:1016322326443PMID 24271526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment

  2004cited by this paper
• Induction of drug metabolizing enzymes by sulfinpyrazone

  2004cited by this paper
• Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol

  2004cited by this paper
• Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. I. Single-Dose Study

  2004cited by this paper
• Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state

  2004cited by this paper
• AUC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis.

  1986cited by this paper
• AUC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis.

  1986cited by this paper
• High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma.

  1984cited by this paper
• The site of reduction of sulphinpyrazone in the rabbit.

  1984cited by this paper
• Inhibition of human platelet cyclo-oxygenase activity by sulfinpyrazone and three of its metabolites.

  1984cited by this paper
• Role of the gut flora in the reduction of sulfinpyrazone in humans.

  1984cited by this paper
• Kinetics and metabolism of sulfinpyrazone

  1983cited by this paper
• A simple integrated method for drug and derived metabolite kinetics. An application of the statistical moment theory.

  1982cited by this paper
• Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.

  1982cited by this paper
• The role of the gut flora in the reduction of sulphinpyrazone in the rat.

  1982cited by this paper
• Clinical Pharmacokinetics and Potentially Important Drug Interactions of Sulphinpyrazone

  1982cited by this paper
• Species differences in the disposition and metabolism of sulfinpyrazone.

  1981cited by this paper
• The effects of two different dosage regimens of sulphinpyrazone on platelet function ex vivo and blood chemistry in man.

  1981cited by this paper
• Sulphinpyrazone metabolism during long-term therapy.

  1981cited by this paper
• The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.

  1981cited by this paper
• Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.

  1981cited by this paper
• Drug metabolite kinetics.

  1981cited by this paper
• New metabolites of sulfinpyrazone in man.

  1980cited by this paper
• Determination of sulfinpyrazone and two of its metabolites in human plasma and urine by gas chromatography and selective detection.

  1979cited by this paper
• Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect.

  1979cited by this paper
• The prolonged effect of sulfinpyrazone on collagen-induced platelet aggregation in vivo.

  1978cited by this paper
• Comparative disposition of sulindac and metabolites in five species.

  1978cited by this paper
• The disposition of sulindac

  1977cited by this paper
• Handbook of basic pharmacokinetics

  1976cited by this paper
• The polymorphic acetylation of dapsone in man

  1971cited by this paper
• Caffeic Acid Metabolism by Bacteria of the Human Gastrointestinal Tract

  1971cited by this paper
• The role of the tissues and gut micro‐organisms in the metabolism of [14C]protocatechuic acid in the rat. Aromatic dehydroxylation

  1968cited by this paper
• A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671.

  1957cited by this paper

• Validation of a Column-Switching High-Performance Liquid Chromatographic (HPLC) Method for Determination of ML-1035 and Its Five Metabolites in Plasma

  2004cites this paper
• Preparation and evaluation of sulfide derivatives of the antibiotic brefeldin a as potential prodrug candidates with enhanced aqueous solubilities.

  2001cites this paper
• Design and synthesis of brefeldin A sulfide derivatives as prodrug candidates with enhanced aqueous solubilities.

  1998cites this paper
• Disposition kinetics of ML-1035 sulfoxide enantiomers and the prochiral sulfide in rats.

  1993cites this paper
• Pharmacokinetics and metabolic interconversion of intravenous 4-amino-5-chloro-2-[(methylsulfinyl)ethoxy]-N-[2-(diethylamino)ethyl] benzamide and its sulfide and sulfone metabolites in rats.

  1993cites this paper